Efficacy, safety, and health-related quality of life in transplant-ineligible newly diagnosed multiple myeloma patients receiving bortezomib maintenance therapy: a study of the Korean Multiple Myeloma Working Party KMMWP-174 study

Authors

Jung Yeon Lee,[1,2*] Seungpil Jung,[3-5*] Suein Choi,[3-5] Sung-Soo Park,[1] Jin Seok Kim,[2] Je-Jung Lee,[6] Seong Kyu Park,[7] Hyo Jung Kim,[8] Gyeong-Won Lee,[9] Young Hoon Park,[10] Hyeon-Seok Eom,[11] Jeong-A Kim,[12] Min Kyoung Kim,[13] Yundeok Kim,[14] Ho-Jin Shin,[15] Ho Sup Lee,[16] Jihyun Kwon[17] and Chang-Ki Min;[1] for the Korean Multiple Myeloma Working Party (KMMWP)

[1]Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul; [2]Division of Hematology, Department of Internal Medicine, Yonsei University College of Medicine, Severance Hospital, Seoul; [3]Pharmacometrics Institute for Practical Education and Training (PIPET), College of Medicine, The Catholic University of Korea, Seoul; [4]Department of Pharmacology, College of Medicine, The Catholic University of Korea, Seoul; [5]Division of Data Science, Catholic Research Network for Multiple Myeloma; [6]Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Hwasun, Jeollanam-do; [7]Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine, Seoul; [8]Department of Hematology-Oncology, Hallym University Medical Center, Hallym University College of Medicine, Anyang; [9]Division of Hematology-Oncology, Department of Internal Medicine, Gyeongsang National University Hospital, Gyeongsang National University College of Medicine, Jinju; [10]Division of Hematology-Oncology, Department of Internal Medicine, Ewha Womans University Medical Center Mokdong Hospital, Seoul; [11]Department of Hematology-Oncology, Center for Hematologic Malignancy, National Cancer Center, Goyang; [12]Department of Internal Medicine, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Seoul; [13]Division of Hemato-Oncology, Department of Internal Medicine, Yeungnam University College of Medicine, Daegu; [14]Division of Hemato-Oncology, Department of Internal Medicine, Wonju Severance Christian Hospital, Wonju; [15]Division of Hematology-Oncology, Department of Internal Medicine, Biochemical Research Institution, Pusan National University Hospital, Pusan National University School of Medicine, Busan; [16]Department of Internal Medicine, Kosin University College of Medicine, Kosin University Gospel Hospital, Busan and [17]Department of Internal Medicine, Hematology and Oncology, Chungbuk National University, College of Medicine, Chungbuk, Republic of Korea

**JYL and SJ contributed equally as first authors.*

Correspondence:
C-K MIN - ckmin@catholic.ac.kr

https://doi.org/10.3324/haematol.2025.287889

Received: March 22, 2025.
Accepted: July 29, 2025.
Early view: August 7, 2025.

Table S1. Induction chemotherapy and Bortezomib maintenance therapy

Variables	Total (N=78)
Induction chemotherapy regimen, number (%)	
VMP	73 (93.6%)
VTD	3 (3.8%)
VD	1 (1.3%)
MP	1 (1.3%)
Induction chemotherapy response, number (%)	
CR	18 (23.1%)
VGPR	36 (46.2%)
PR	24 (30.8%)
Bortezomib maintenance therapy cycles, number, median (range)	9.5 (1-26)
Bortezomib maintenance therapy duration, months, median (range)	9.4 (0.9-26.4)

*Abbreviations: VMP, bortezomib-melphalan-prednisone; VTD, bortezomib-thalidomide-dexamethasone; VD, bortezomib-dexamethasone; MP, melphalan-prednisone; CR, complete response; VGPR, very good partial response; PR, partial response

Table S2. EORTC-QLQ-C30 and EORTC-QLQ-MY20 scores of MM patients at baseline and end of treatment

Variables[1]	Baseline (N = 78)	EoT (N = 73)	P-value[2]
Global health status / QoL	61.32 (18.94)	56.05 (20.85)	0.040
Functional scales	78.68 (15.95)	74.51 (15.65)	0.006
Physical functioning	74.89 (20.35)	73.70 (17.42)	0.210
Role functioning	74.79 (23.07)	71.69 (20.16)	0.045
Emotional functioning	84.72 (16.96)	78.54 (21.33)	0.005
Cognitive functioning	82.91 (15.19)	75.80 (20.04)	<0.001
Social functioning	75.64 (23.68)	69.86 (25.25)	0.037
Symptom scales / items	18.47 (14.53)	20.05 (12.06)	0.243
Fatigue	27.78 (20.94)	31.05 (17.66)	0.084
Nausea and vomiting	4.06 (11.45)	4.34 (8.35)	0.748
Pain	24.57 (25.44)	23.97 (21.51)	0.948
Dyspnea	20.51 (29.04)	21.00 (23.90)	0.704
Insomnia	20.09 (25.39)	20.55 (25.23)	0.795
Appetite loss	17.52 (24.46)	17.81 (23.62)	0.683
Constipation	15.81 (25.61)	15.98 (22.30)	0.726
Diarrhea	6.41 (16.17)	7.41 (16.99)	0.829
Financial difficulties	19.23 (24.33)	28.24 (28.34)	0.009
EORTC-QLQ-MY20			
Disease symptoms	17.82 (14.66)	20.09 (13.88)	0.187
Side-effects of treatment	14.64 (12.97)	16.44 (10.86)	0.124
Body image	78.21 (24.52)	73.06 (26.44)	0.080
Future perspective	69.94 (22.73)	63.17 (26.64)	0.030

[1]All variables are summarized by Mean (SD)
[2]Paired t-test of 73 patients
*Abbreviations: EORTC, European Organization for Research and Treatment of Cancer; QLQ-C30: Quality of Life Questionnaire Core-30; QLQ-MY20, Quality of Life Questionnaire Myeloma Module (QLQ-MY20); SD, Standard Deviation; QoL, Quality of Life; EoT, End of Treatment;

Figure S1. Forest plot for comparing 2-year survival rate of each group